Zeke Capital Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Zeke Capital Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12,071	Closed	-$28K	–	799
2018 Q2	$28K	Hold	12,071	–	–	﹤0.01%	633
2018 Q1	$35K	Sell	12,071 -5,123	-30%	-$14K	﹤0.01%	642
2017 Q4	$47K	Buy	+17,194	New	+$52.8K	﹤0.01%	555

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Zeke Capital Advisors's PDLI Position: Q3 2018 in Review

Zeke Capital Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 12,071 shares — an estimated $28K sold.

Zeke Capital Advisors first reported a position in PDLI in Q4 2017 and held it in 3 quarters. The position peaked at $47K in Q4 2017. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Zeke Capital Advisors reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Zeke Capital Advisors sold 12,071 PDL BioPharma, Inc. shares in Q3 2018, an estimated $28K.
Zeke Capital Advisors first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 3 quarters.
Zeke Capital Advisors's PDL BioPharma, Inc. position peaked at $47K in Q4 2017.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Zeke Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.